Polycystic Ovarian Syndrome (PCOS) Treatment Market 2027 by Types, Application, Technology, Opportunities, End Users and Regions | The Insight Partners

Polycystic Ovarian Syndrome (PCOS) Treatment Market to 2027 - Global Analysis and Forecasts by Drug Class (Contraceptives, Anti-Depressants, Insulin Sensitizing Agents, Diuretics, Aromatase Inhibitors, Ornithine Decarboxylase Inhibitors); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography

Report Code: TIPRE00004072 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
MARKET INTRODUCTION
Polycystic ovary syndrome (PCOS) is a hormonal disorder, which is a common health problem caused by an imbalance of reproductive hormones. Women with PCOS have metabolism problems that affect their overall health and appearance. PCOS can cause missed or irregular menstrual periods and an irregular periods can lead to infertility and development of cysts (small fluid-filled sacs) in the ovaries. The medications for such conditions include oral contraceptives, metformin, prednisone, leuprolide, clomiphene and spironolactone.

MARKET DYNAMICS
The polycystic ovarian syndrome (PCOS) treatment market is anticipated to grow due to the key driving factors such as rising genetic & hormonal disorders and a growing awareness among the patient population. However, growing popularity of combination drugs and their rising adoption among the patient population are likely to grow the market during the forecast period.

MARKET SCOPE
The "Global Polycystic Ovarian Syndrome (PCOS) Treatment Market Analysis to 2027" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of polycystic ovarian syndrome (PCOS) treatment market with detailed market segmentation by drug class and distribution channel. The global polycystic ovarian syndrome (PCOS) treatment market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading polycystic ovarian syndrome (PCOS) treatment market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION
The global polycystic ovarian syndrome (PCOS) treatment market is segmented on the basis of drug class and distribution channel. On the basis of drug class, the market is segmented as, contraceptives, anti-depressants, insulin sensitizing agents, diuretics, aromatase inhibitors and ornithine decarboxylase inhibitors. Based on distribution channel, the polycystic ovarian syndrome (PCOS) treatment market is categorized as hospital pharmacies, retail pharmacies and online pharmacies.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global polycystic ovarian syndrome (PCOS) treatment market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The polycystic ovarian syndrome (PCOS) treatment market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting polycystic ovarian syndrome (PCOS) treatment market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the polycystic ovarian syndrome (PCOS) treatment market in these regions.

MARKET PLAYERS
The reports cover key developments in the polycystic ovarian syndrome (PCOS) treatment market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from polycystic ovarian syndrome (PCOS) treatment market are anticipated to lucrative growth opportunities in the future with the rising demand for polycystic ovarian syndrome (PCOS) treatment market in the global market. Below mentioned is the list of few companies engaged in the polycystic ovarian syndrome (PCOS) treatment market.

The report also includes the profiles of key polycystic ovarian syndrome (PCOS) treatment market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
  • Sanofi
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Merck KGaA
  • Bristol-Myers Squibb Company
  • AstraZeneca
  • ADDEX THERAPEUTICS
  • BIOCAD
  • Ferring B.V.
  • CRINETICS PHARMACEUTICALS
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Polycystic Ovarian Syndrome (PCOS) Treatment Market - By Drug Class
1.3.2 Polycystic Ovarian Syndrome (PCOS) Treatment Market - By Distribution Channel
1.3.3 Polycystic Ovarian Syndrome (PCOS) Treatment Market - By Region
1.3.3.1 By Country
2. KEY TAKEWAYS
3. RESEARCH METHODOLOGY
4. POLYCYSTIC OVARIAN SYNDROME (PCOS) TREATMENT MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. POLYCYSTIC OVARIAN SYNDROME (PCOS) TREATMENT MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. POLYCYSTIC OVARIAN SYNDROME (PCOS) TREATMENT MARKET - GLOBAL MARKET ANALYSIS
6.1. POLYCYSTIC OVARIAN SYNDROME (PCOS) TREATMENT - GLOBAL MARKET OVERVIEW
6.2. POLYCYSTIC OVARIAN SYNDROME (PCOS) TREATMENT - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. POLYCYSTIC OVARIAN SYNDROME (PCOS) TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 - DRUG CLASS
7.1. OVERVIEW
7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
7.3. CONTRACEPTIVES
7.3.1. Overview
7.3.2. Contraceptives Market Forecast and Analysis
7.4. ANTI-DEPRESSANTS
7.4.1. Overview
7.4.2. Anti-Depressants Market Forecast and Analysis
7.5. INSULIN SENSITIZING AGENTS
7.5.1. Overview
7.5.2. Insulin Sensitizing Agents Market Forecast and Analysis
7.6. DIURETICS
7.6.1. Overview
7.6.2. Diuretics Market Forecast and Analysis
7.7. AROMATASE INHIBITORS
7.7.1. Overview
7.7.2. Aromatase Inhibitors Market Forecast and Analysis
7.8. ORNITHINE DECARBOXYLASE INHIBITORS
7.8.1. Overview
7.8.2. Ornithine Decarboxylase Inhibitors Market Forecast and Analysis
8. POLYCYSTIC OVARIAN SYNDROME (PCOS) TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 - DISTRIBUTION CHANNEL
8.1. OVERVIEW
8.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
8.3. HOSPITAL PHARMACIES
8.3.1. Overview
8.3.2. Hospital Pharmacies Market Forecast and Analysis
8.4. RETAIL PHARMACIES
8.4.1. Overview
8.4.2. RETAIL PHARMACIES Market Forecast and Analysis
8.5. ONLINE PHARMACIES
8.5.1. Overview
8.5.2. Online Pharmacies Market Forecast and Analysis
9. POLYCYSTIC OVARIAN SYNDROME (PCOS) TREATMENT MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Polycystic Ovarian Syndrome (PCOS) Treatment Market Overview
9.1.2 North America Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecasts and Analysis
9.1.3 North America Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecasts and Analysis - By Drug Class
9.1.4 North America Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecasts and Analysis - By Distribution Channel
9.1.5 North America Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecasts and Analysis - By Countries
9.1.5.1 United States Polycystic Ovarian Syndrome (PCOS) Treatment Market
9.1.5.1.1 United States Polycystic Ovarian Syndrome (PCOS) Treatment Market by Drug Class
9.1.5.1.2 United States Polycystic Ovarian Syndrome (PCOS) Treatment Market by Distribution Channel
9.1.5.2 Canada Polycystic Ovarian Syndrome (PCOS) Treatment Market
9.1.5.2.1 Canada Polycystic Ovarian Syndrome (PCOS) Treatment Market by Drug Class
9.1.5.2.2 Canada Polycystic Ovarian Syndrome (PCOS) Treatment Market by Distribution Channel
9.1.5.3 Mexico Polycystic Ovarian Syndrome (PCOS) Treatment Market
9.1.5.3.1 Mexico Polycystic Ovarian Syndrome (PCOS) Treatment Market by Drug Class
9.1.5.3.2 Mexico Polycystic Ovarian Syndrome (PCOS) Treatment Market by Distribution Channel
9.2. EUROPE
9.2.1 Europe Polycystic Ovarian Syndrome (PCOS) Treatment Market Overview
9.2.2 Europe Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecasts and Analysis
9.2.3 Europe Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecasts and Analysis - By Drug Class
9.2.4 Europe Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecasts and Analysis - By Distribution Channel
9.2.5 Europe Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Polycystic Ovarian Syndrome (PCOS) Treatment Market
9.2.5.1.1 Germany Polycystic Ovarian Syndrome (PCOS) Treatment Market by Drug Class
9.2.5.1.2 Germany Polycystic Ovarian Syndrome (PCOS) Treatment Market by Distribution Channel
9.2.5.2 France Polycystic Ovarian Syndrome (PCOS) Treatment Market
9.2.5.2.1 France Polycystic Ovarian Syndrome (PCOS) Treatment Market by Drug Class
9.2.5.2.2 France Polycystic Ovarian Syndrome (PCOS) Treatment Market by Distribution Channel
9.2.5.3 Italy Polycystic Ovarian Syndrome (PCOS) Treatment Market
9.2.5.3.1 Italy Polycystic Ovarian Syndrome (PCOS) Treatment Market by Drug Class
9.2.5.3.2 Italy Polycystic Ovarian Syndrome (PCOS) Treatment Market by Distribution Channel
9.2.5.4 Spain Polycystic Ovarian Syndrome (PCOS) Treatment Market
9.2.5.4.1 Spain Polycystic Ovarian Syndrome (PCOS) Treatment Market by Drug Class
9.2.5.4.2 Spain Polycystic Ovarian Syndrome (PCOS) Treatment Market by Distribution Channel
9.2.5.5 United Kingdom Polycystic Ovarian Syndrome (PCOS) Treatment Market
9.2.5.5.1 United Kingdom Polycystic Ovarian Syndrome (PCOS) Treatment Market by Drug Class
9.2.5.5.2 United Kingdom Polycystic Ovarian Syndrome (PCOS) Treatment Market by Distribution Channel
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Treatment Market Overview
9.3.2 Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecasts and Analysis
9.3.3 Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecasts and Analysis - By Drug Class
9.3.4 Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecasts and Analysis - By Distribution Channel
9.3.5 Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Polycystic Ovarian Syndrome (PCOS) Treatment Market
9.3.5.1.1 Australia Polycystic Ovarian Syndrome (PCOS) Treatment Market by Drug Class
9.3.5.1.2 Australia Polycystic Ovarian Syndrome (PCOS) Treatment Market by Distribution Channel
9.3.5.2 China Polycystic Ovarian Syndrome (PCOS) Treatment Market
9.3.5.2.1 China Polycystic Ovarian Syndrome (PCOS) Treatment Market by Drug Class
9.3.5.2.2 China Polycystic Ovarian Syndrome (PCOS) Treatment Market by Distribution Channel
9.3.5.3 India Polycystic Ovarian Syndrome (PCOS) Treatment Market
9.3.5.3.1 India Polycystic Ovarian Syndrome (PCOS) Treatment Market by Drug Class
9.3.5.3.2 India Polycystic Ovarian Syndrome (PCOS) Treatment Market by Distribution Channel
9.3.5.4 Japan Polycystic Ovarian Syndrome (PCOS) Treatment Market
9.3.5.4.1 Japan Polycystic Ovarian Syndrome (PCOS) Treatment Market by Drug Class
9.3.5.4.2 Japan Polycystic Ovarian Syndrome (PCOS) Treatment Market by Distribution Channel
9.3.5.5 South Korea Polycystic Ovarian Syndrome (PCOS) Treatment Market
9.3.5.5.1 South Korea Polycystic Ovarian Syndrome (PCOS) Treatment Market by Drug Class
9.3.5.5.2 South Korea Polycystic Ovarian Syndrome (PCOS) Treatment Market by Distribution Channel
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Polycystic Ovarian Syndrome (PCOS) Treatment Market Overview
9.4.2 Middle East and Africa Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecasts and Analysis
9.4.3 Middle East and Africa Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecasts and Analysis - By Drug Class
9.4.4 Middle East and Africa Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecasts and Analysis - By Distribution Channel
9.4.5 Middle East and Africa Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Polycystic Ovarian Syndrome (PCOS) Treatment Market
9.4.5.1.1 South Africa Polycystic Ovarian Syndrome (PCOS) Treatment Market by Drug Class
9.4.5.1.2 South Africa Polycystic Ovarian Syndrome (PCOS) Treatment Market by Distribution Channel
9.4.5.2 Saudi Arabia Polycystic Ovarian Syndrome (PCOS) Treatment Market
9.4.5.2.1 Saudi Arabia Polycystic Ovarian Syndrome (PCOS) Treatment Market by Drug Class
9.4.5.2.2 Saudi Arabia Polycystic Ovarian Syndrome (PCOS) Treatment Market by Distribution Channel
9.4.5.3 U.A.E Polycystic Ovarian Syndrome (PCOS) Treatment Market
9.4.5.3.1 U.A.E Polycystic Ovarian Syndrome (PCOS) Treatment Market by Drug Class
9.4.5.3.2 U.A.E Polycystic Ovarian Syndrome (PCOS) Treatment Market by Distribution Channel
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Polycystic Ovarian Syndrome (PCOS) Treatment Market Overview
9.5.2 South and Central America Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecasts and Analysis
9.5.3 South and Central America Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecasts and Analysis - By Drug Class
9.5.4 South and Central America Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecasts and Analysis - By Distribution Channel
9.5.5 South and Central America Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Polycystic Ovarian Syndrome (PCOS) Treatment Market
9.5.5.1.1 Brazil Polycystic Ovarian Syndrome (PCOS) Treatment Market by Drug Class
9.5.5.1.2 Brazil Polycystic Ovarian Syndrome (PCOS) Treatment Market by Distribution Channel
9.5.5.2 Argentina Polycystic Ovarian Syndrome (PCOS) Treatment Market
9.5.5.2.1 Argentina Polycystic Ovarian Syndrome (PCOS) Treatment Market by Drug Class
9.5.5.2.2 Argentina Polycystic Ovarian Syndrome (PCOS) Treatment Market by Distribution Channel
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. POLYCYSTIC OVARIAN SYNDROME (PCOS) TREATMENT MARKET, KEY COMPANY PROFILES
11.1. SANOFI
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. NOVARTIS AG
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. TEVA PHARMACEUTICAL INDUSTRIES LTD.
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. MERCK KGAA
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. BRISTOL-MYERS SQUIBB COMPANY
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. ASTRAZENECA
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. ADDEX THERAPEUTICS
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. BIOCAD
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. FERRING B.V.
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. CRINETICS PHARMACEUTICALS
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies

1. Sanofi
2. Novartis AG
3. Teva Pharmaceutical Industries Ltd.
4. Merck KGaA
5. Bristol-Myers Squibb Company
6. AstraZeneca
7. ADDEX THERAPEUTICS
8. BIOCAD
9. Ferring B.V.
10. CRINETICS PHARMACEUTICALS
Select License Type
USD $3000
USD $4550
USD $6550
USD $8550

Free

20%

customization on Pre-Booking
Pre Book